Now that we have commercial access to BCMA Bispecifics in Myeloma, how important is it to have an assay for sBCMA? How would one use it in clinical practice?

#ASCO26 #mmsm Oral sessions myeloma PERSEUS outcomes based on new definition of high risk disease Sustained MRD negativity seem to make the outcome of high risk similar to standard risk, imp to be sustained over multiple years

Used The PedsQL 4.0 Generic Core Scales to assess QOL. Significant Overall Improvement: The transplant (Tx) group scored significantly higher across all domains of health-related quality of life compared to the non-transplant (NTx) group (p < 0.05). This includes improvements

3/ @ASCO #ASCO26 #myeloma #mmsm - Impact of 5-Year Sustained MRD negativity in FORTE asco.org/abstracts-presentat… - cfDNA WGS vs Mass Spec asco.org/abstracts-presentat… And one bonus thought-provoking on differences in access to CARTs asco.org/abstracts-presentat…

How do you manage Progressive Disease in Myeloma post Bispecifics ( Teclistamab )? Is there any approach? Can we induce sensitivity of Bispecifics- Plasma exchange /-DTPACE/IMid like Therapy? @RahulBanerjeeMD @VincentRK @myelomaMD @Rfonsi1 @rajshekharucms @kansagraM

Hematologists treat acute leukemias at most centers across the country . Excluding hematologists from clinical trials of “HEMATOLOGICAL MALIGNANCIES “ makes absolutely no sense and is an irony in itself . Really unfortunate that instead of widening access to patients , policy decisions ignore ground realities and come up with such absurd ideas @jayastuMD @royjpalatty @VergheseRenjith @chepsyphilip @TK2K6 @ishbtish @hematologydr @TribikramHemat @TikareNakul @Rohanhematdoc @shanuaswam @RahulDoc2 @dranupjdevasia

Has the @CDSCO_INDIA_INF conveniently forgotten that there are #hematologists who are specially trained to treat #bloodcancers ? This order has surprised me as I was a member of the Subject Expert Committee of CDSCO on #HematologyOncology for more than 5 years. If CDSCO feels hematooncologists are not competent to conduct #clinicaltrials on patients with blood cancers then should we stop treating these patients ? @NMC_IND @MoHFW_INDIA @DrPMPGI @RahulDoc2 @drtulikahemat

Not all wins are measured in survival curves, some are felt in everyday life. @dbhurani @Rohanhematdoc @narendra_ag1 #Thalassemia #HRQoL #Hemoglobin @MoHFW_INDIA

First Indian study to directly compare dasatinib de-escalation vs upfront low-dose strategy in newly diagnosed chronic-phase CML patients, addressing a major gap in real-world Indian data. #CML #de_escalation @dbhurani @SujayRainchwar @Rohanhematdoc @narendra_ag1 @leukemia

What's going to be different with the new IMWG response criteria? Main changes: - FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone) - No more sCR - Bone marrow to confirm CR can be performed /- 6 weeks from blood testing. - 24-hour urine at baseline, and if M-protein present, retest only to confirm CR - Patients can be considered to have PD if they meet criteria by a variable not considered measurable at baseline (major weakness with current response criteria is that it misses light chain escape). Next, imaging....

𝗙𝘂𝗹𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹, 𝗳𝘂𝗹𝗹 𝗱𝗼𝗺𝗶𝗻𝗮𝗻𝗰𝗲! 🔥 🇮🇳 India round up the Pool stages of the Hero Asia Cup Rajgir, Bihar 2025 with a emphatic 15-0 triumph over Kazakhstan. #HockeyIndia #IndiaKaGame #HumSeHaiHockey #HeroAsiaCupRajgir